Drug resistance in Leishmania: does it really matter?

Domagalska, Malgorzata A.; Barrett, Michael P.; Dujardin, Jean Claude

doi:10.1016/j.pt.2023.01.012

Cited by 13 publications

(9 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several investigations have been performed to assess the likely impact of the SARS‐CoV‐2 pandemic on different facets of life, health, and underlying health system parameters such as costs, antibiotic resistance, physiological effects, and possible interaction with other diseases 16–18,29,30,35,48,49,53,54 . There is still no specific, completely safe, and appropriate drug, method, or vaccine for the treatment or prevention of CL, as well as the occurrence of secondary infections at the wound site and the need to take other antibiotics, along with the emergence of resistance to anti‐leishmanial and antibacterial agents, makes the treatment of this infection more complicated 73–79 . Despite the introduction of several types of different treatments (Traditional medicines, treatment with stem cells and their derivatives, chemical compounds, cryotherapy, etc.…”

Section: Discussionmentioning

confidence: 99%

Real‐time impact of COVID‐19 pandemic on cutaneous leishmaniasis case finding and strategic planning, preventive interventions, control and epidemiology in a region with a high burden of cutaneous leishmaniasis and COVID‐19: A cross‐sectional descriptive study based on registry data in Ilam‐Iran

Shams,

Rashidi,

Mohamadi

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Background and AimsCutaneous leishmaniasis (CL) is a severe parasitic disease affecting people, mostly in underdeveloped nations. As a zoonotic infection yearly incidence of CL depends on several parameters such as demographic, epidemiological, and environmental factors as well as prevention and control measures. The sudden outbreak of pandemics such as SARS‐Corona‐Virus‐2 pandemic, can probably affect the incidence or reporting of other diseases, especially infectious diseases, in various ways such as pressure on health systems, providing sanitary services and its components, lockdowns and changes in people's living habits.AimThis study aimed to evaluate the COVID‐19 impact on the incidence and other epidemiological aspects as well as control measures of CL in Ilam Province‐Iran.MethodsRequired data was extracted from the CL registration system in Ilam from 2014 to 2021 to demonstrate the trend of CL incidence before and after COVID‐19 pandemic.ResultsBased on our results, a declining pattern of CL incidence was observed, accompanied by the advent and intensification of the viral pandemic in Iran and Ilam province. Although, this decreasing pattern was not integral in all areas, and even increase in CL detection was emphasized in some regions.ConclusionIt may be inferred that the COVID‐19 pandemic may disrupt treatment programs of CL cases, rodent nest destruction, and fighting vector insects.

show abstract

Section: Discussionmentioning

confidence: 99%

Real‐time impact of COVID‐19 pandemic on cutaneous leishmaniasis case finding and strategic planning, preventive interventions, control and epidemiology in a region with a high burden of cutaneous leishmaniasis and COVID‐19: A cross‐sectional descriptive study based on registry data in Ilam‐Iran

Shams,

Rashidi,

Mohamadi

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

show abstract

“…La resistencia a los fármacos es un desafío importante para el tratamiento de la leishmaniasis, ya que limita la eficacia de los tratamientos y puede conducir a una mayor morbimortalidad en los pacientes. Se necesitan más investigaciones para comprender la frecuencia y los mecanismos de la resistencia a los fármacos en la leishmaniasis y desarrollar estrategias efectivas para prevenir y tratar la resistencia a los fármacos (32).…”

Section: Principales Microorganismos Farmacorresistentes Parasitariosunclassified

Resistencia Antimicrobiana

Larrea¹,

Segarra²,

Sisalima³

et al. 2023

Infectología Clínica

View full text Add to dashboard Cite

Resumen: La resistencia antimicrobiana constituye un problema de salud pública, es un proceso en el cual un microorganismo sobrevive ante los efectos de antimicrobianos, un mecanismo de supervivencia, disminuyendo la capacidad microbicida del antimicrobiano, siendo una temática importante para analizarse hoy en día, por lo cual es necesario realizar esta revisión. Existen diferentes mecanismos de resistencia como a nivel del material genético tenemos limitar su acceso, deshacerse del fármaco, destruir el medicamento, eludir efectos del medicamento y cambiar los objetivos del medicamento; en cambio a nivel extracelular fabricar biopelículas, intervención del sistema quorum sensing; a nivel de la envoltura celular, impermeabilidad de membranas, porinas de membranas, bombas de expulsión e inhibición de la síntesis de la pared celular; y a nivel intracelular tenemos sistemas de protección ribosomal y modificación del sitio activo. La bacteria farmacorresistente más destacada es la Escherichia Coli, siendo las ß-lactamasas de espectro extendido el tipo de resistencia más común a nivel de América y el mundo. En relación a virus, producen inmunosupresión, por tal motivo se relaciona especialmente con el Virus de la Inmunodeficiencia Humana. En relación con los hongos, se ha reconocido a la Cándida Albincans como el microorganismo más frecuente farmacorresistente. Y con relación a los parásitos, tenemos a Plasmodium falciparum y Schistosoma spp. Al tener una gran magnitud y ser una problemática creciente, se debe tomar en cuenca planes, guías, campañas, vigilancia epidemiológica, educación profesional médica y a la sociedad, sobre las complicaciones que podríamos evitar si estamos correctamente informados.

show abstract

“… 2 , 3 Due to the limited number of drugs with similar efficacy and availability, 4 multiple efforts have been undertaken to understand the basis of resistance to antimonial drugs and its relationship with treatment failure. 5 , 6 DR has mostly been studied following in vitro selection of drug-resistant populations, and only few studies have evaluated the drug susceptibility profile of circulating clinical strains of Leishmania. 3 , 7 Two subpopulations of Leishmania (Viannia) panamensis , distinguished by isoenzyme profiles defined as zymodemes, showed divergent susceptibility to antimonial drugs in vitro .…”

Section: Introductionmentioning

confidence: 99%

The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils

Díaz-Varela,

Sanchez-Hidalgo,

Calderon-Copete

et al. 2024

iScience

View full text Add to dashboard Cite

Drug resistance in Leishmania: does it really matter?

Cited by 13 publications

References 53 publications

Resistencia Antimicrobiana

The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils

Contact Info

Product

Resources

About